Related Experiment Video
Updated: May 4, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
Published on: August 13, 2019
Extended duration use of menopausal hormone therapy
1From the University of Florida College of Medicine-Jacksonville, Department of Obstetrics & Gynecology, Jacksonville, FL.
Abstract:
Although providing guidance to patients regarding duration of hormone therapy represents a topic surrounded by controversy, clinicians often encounter this issue in practice. As pointed out in the NAMS 2012 Hormone Therapy (HT) Position Statement, determining the optimal duration of HT is challenging both for clinicians and for patients. This Practice Pearl addresses clinical situations for which long-term HT might be appropriate and provides practical guidance regarding prudent therapeutic choices for women using HT for an extended duration.
More Related Videos
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
14:26A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
Published on: April 7, 2014
Related Concept Videos
Menopause
Intrauterine Drug Delivery Systems
Pharmacokinetic–Pharmacodynamic Relationship: Influence of Elimination Half-Life on Effect Duration
Oral Drug Delivery Systems: Continuous-Release Systems
Hormonal Regulation of the Menstrual Cycle
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
Modified-Release Drug Delivery Systems: Overview